A new multinational study analyzing data from over 230 million people across 20 global sites highlights the relationship ...

A global study, covering more than 230 million people, sheds light on the relationship between Guillain-Barré syndrome after ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca (NASDAQ:AZN)’s experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease ...

Snapping two week losing Streak Sensex surged 737.98 points or 0.90 per cent to settle at 82,188.99 during the week ended ...

The Health Ministry has urged health facilities to stay alert and increase surveillance of COVID-19 amid a surge in cases ...

And Sanofi has a path to adequate returns. Boards, Policy & Regulationcategory· June 1, 2025 Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk Treating breast ...

AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by Pfizer. Now, he thinks ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as a "growing global hub" for clinical trials. The C$820 million ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Camizestrant and AstraZeneca still have a lot of competition in this space but their novel strategy could help them carve a niche. Credit: Ground Picture via Shutterstock. AstraZeneca has presented ...